The latest price target for UroGen Pharma (NASDAQ:URGN) was reported by Guggenheim on August 22, 2024. The analyst firm set a price target for $40.00 expecting URGN to rise to within 12 months (a possible 195.42% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for UroGen Pharma (NASDAQ:URGN) was provided by Guggenheim, and UroGen Pharma initiated their buy rating.

There is no last upgrade for UroGen Pharma

The last downgrade for UroGen Pharma Ltd happened on February 8, 2023 when Jefferies changed their price target from $35 to $10 for UroGen Pharma Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of UroGen Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for UroGen Pharma was filed on August 22, 2024 so you should expect the next rating to be made available sometime around August 22, 2025.

While ratings are subjective and will change, the latest UroGen Pharma (URGN) rating was a initiated with a price target of $0.00 to $40.00. The current price UroGen Pharma (URGN) is trading at is $13.54, which is within the analyst’s predicted range.